Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,378 across all filing types
Latest filing 2019-06-11 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
GRANT OF SHARE OPTIONS
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the grant of share options to employees under the Post-IPO ESOP plan. It details the number of options granted, the subscription price, vesting schedule, and the purpose of the grant. It is made pursuant to Rule 17.06A of the Listing Rules, which relates to share option grants. The document is not a full financial report, earnings release, or management discussion, but a specific announcement about share options granted. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or stock options. The document length is 5668 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is SHA with high confidence.
2019-06-11 English
VOLUNTARY ANNOUNCEMENT - CSTONE AND BAYER ANNOUNCE GLOBAL CLINICAL COLLABORATION TO EVALUATE PD-L1 MONOCLONAL ANTIBODY CS1001 IN COMBINATION WITH REGORAFENIB
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals about entering into a global clinical collaboration with Bayer to evaluate a drug combination for cancer treatment. It contains no financial data, no regulatory filings, no voting results, no management changes, no earnings or annual report content. It is a corporate announcement about a strategic collaboration and clinical trial initiation. The document length is 7947 characters, which is substantial but the content is clearly an announcement rather than a report or transcript. There is no indication of financial results or detailed financial analysis. Therefore, the document fits best into the category of a Regulatory Filing (RNS) as a general corporate announcement that does not fit other specific categories.
2019-06-10 English
VOLUNTARY ANNOUNCEMENT - CSTONE RECEIVED APPROVAL TO INITIATE CLINICAL DEVELOPMENT IN CHINA OF CS1001 AND BLU-554 (CS3008) FOR HCC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the approval to initiate clinical development of two drug candidates for hepatocellular carcinoma (HCC) in China. It contains detailed information about the clinical trial, drug candidates, company background, and partnership details. There are no financial statements, regulatory certifications, voting results, or management changes. The document is an announcement of a clinical development milestone rather than a financial report, regulatory filing, or management update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a voluntary announcement about a clinical trial approval, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2019
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/05/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share-related movements. It includes confirmations by a director regarding compliance with listing rules and legal requirements. The content focuses on share capital changes and securities issuance movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements and confirmations to the exchange, not a full financial report or earnings release. Therefore, it fits best under 'Regulatory Filings' (RNS) as a general regulatory announcement about share capital movements and compliance confirmations.
2019-06-05 English
Monthly Returns
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 31/05/2019. The content focuses on share capital changes and related securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital movements for a specific month, consistent with disclosures required by stock exchanges for equity issuers. The document is not an annual or interim report, earnings release, or management discussion. It is a regulatory announcement about share capital movements, fitting best under Regulatory Filings (RNS).
2019-06-03 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (285 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another filing. Per the 'Menu vs Meal' rule, this is a notification of a publication rather than the report itself, fitting the definition of a Report Publication Announcement.
2019-06-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.